CN114269941A - 基于脱靶评估评价基因编辑治疗的方法 - Google Patents

基于脱靶评估评价基因编辑治疗的方法 Download PDF

Info

Publication number
CN114269941A
CN114269941A CN202080058282.4A CN202080058282A CN114269941A CN 114269941 A CN114269941 A CN 114269941A CN 202080058282 A CN202080058282 A CN 202080058282A CN 114269941 A CN114269941 A CN 114269941A
Authority
CN
China
Prior art keywords
target
genetically modified
site
gene editing
target marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080058282.4A
Other languages
English (en)
Inventor
袁鹏飞
方日国
金鸣
张永建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Ji Yin Medical Technology Co ltd
Original Assignee
Edigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edigene Inc filed Critical Edigene Inc
Publication of CN114269941A publication Critical patent/CN114269941A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

一种确定细胞疗法对个体的适合性的方法。利用生物信息学方法和无偏向的潜在脱靶位点实验分析方法，在向个体施用细胞疗法前对源自个体的基因修饰细胞的潜在脱靶位点进行预测，并在将源自个体的基因修饰细胞施用至个体后对潜在脱靶位点进行监测，确定所述潜在脱靶位点否发生基因编辑，并基于基因编辑事件的发生评估所述治疗的适合性。

Description

PCT国内申请，说明书已公开。

Claims (35)

  1. PCT国内申请，权利要求书已公开。
CN202080058282.4A 2019-09-04 2020-09-04 基于脱靶评估评价基因编辑治疗的方法 Pending CN114269941A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/104303 2019-09-04
CN2019104303 2019-09-04
PCT/CN2020/113562 WO2021043278A1 (zh) 2019-09-04 2020-09-04 基于脱靶评估评价基因编辑治疗的方法

Publications (1)

Publication Number Publication Date
CN114269941A true CN114269941A (zh) 2022-04-01

Family

ID=74852757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058282.4A Pending CN114269941A (zh) 2019-09-04 2020-09-04 基于脱靶评估评价基因编辑治疗的方法

Country Status (8)

Country Link
US (1) US20220340969A1 (zh)
EP (1) EP4026910A1 (zh)
JP (1) JP2022547105A (zh)
KR (1) KR20220053671A (zh)
CN (1) CN114269941A (zh)
AU (1) AU2020342207A1 (zh)
CA (1) CA3150230A1 (zh)
WO (1) WO2021043278A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220307020A1 (en) 2019-04-15 2022-09-29 Edigene Inc. Methods and compositions for editing rnas
EP3997229A4 (en) 2019-07-12 2024-07-03 Univ Beijing TARGETED RNA EDITING BY HARNESSING ENDOGENOUS ADAR USING MODIFIED RNA

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109735574A (zh) * 2017-10-27 2019-05-10 博雅辑因（北京）生物科技有限公司 一种提高胎儿血红蛋白表达的方法
CN109789185A (zh) * 2016-07-28 2019-05-21 基础科学研究院 用于治疗眼部疾病的含cas9蛋白和向导rna的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038850T2 (hu) 2012-05-25 2018-11-28 Univ California Eljárások és kompozíciók cél-DNS RNS-irányított módosításához és transzkripció RNS-irányított modulálásához
AU2013293270B2 (en) 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
CN110066775B (zh) 2012-10-23 2024-03-19 基因工具股份有限公司 用于切割靶dna的组合物及其用途
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN108351350B (zh) * 2015-08-25 2022-02-18 杜克大学 使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法
EP3450570B1 (en) * 2016-04-28 2021-03-10 Industry-Academic Cooperation Foundation, Yonsei University Method for evaluating, in vivo, activity of rna-guided nuclease in high-throughput manner
MX2018013445A (es) * 2016-05-06 2019-09-09 Juno Therapeutics Inc Celulas diseñadas geneticamente y metodos para obtener las mismas.
KR102558931B1 (ko) * 2017-06-23 2023-07-21 인스크립타 인코포레이티드 핵산 가이드 뉴클레아제
WO2019052577A1 (zh) * 2017-09-18 2019-03-21 博雅辑因（北京）生物科技有限公司 一种基因编辑t细胞及其用途
EP3697907A1 (en) * 2017-10-17 2020-08-26 CRISPR Therapeutics AG Compositions and methods for gene editing for hemophilia a
CN107967411B (zh) * 2017-11-21 2021-09-10 南方科技大学 一种脱靶位点的检测方法、装置及终端设备
CN109868283B (zh) * 2019-02-21 2021-07-20 浙江农林大学 一种评估CRISPR/Cas9基因编辑效率或脱靶频率的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789185A (zh) * 2016-07-28 2019-05-21 基础科学研究院 用于治疗眼部疾病的含cas9蛋白和向导rna的药物组合物
CN109735574A (zh) * 2017-10-27 2019-05-10 博雅辑因（北京）生物科技有限公司 一种提高胎儿血红蛋白表达的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王影等: "CRISPR/Cas9基因组定点编辑中脱靶现象的研究进展", 植物学报, vol. 53, no. 4, pages 528 - 541 *

Also Published As

Publication number Publication date
US20220340969A1 (en) 2022-10-27
KR20220053671A (ko) 2022-04-29
WO2021043278A1 (zh) 2021-03-11
EP4026910A1 (en) 2022-07-13
JP2022547105A (ja) 2022-11-10
CA3150230A1 (en) 2021-03-11
AU2020342207A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
CN109735497B (zh) 一种提高胎儿血红蛋白表达水平的方法
Schumann et al. Functional CRISPR dissection of gene networks controlling human regulatory T cell identity
Vionnie et al. Epigenetic memory underlies cell-autonomous heterogeneous behavior of hematopoietic stem cells
EP3964579A1 (en) Method for predicting effectiveness of treatment of hemoglobinopathy
CN114269941A (zh) 基于脱靶评估评价基因编辑治疗的方法
Shi et al. Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells
Zhang et al. Ex vivo expansion potential of murine hematopoietic stem cells is a rare property only partially predicted by phenotype
Martin et al. Dynamics of chromatin accessibility during hematopoietic stem cell differentiation into progressively lineage-committed progeny
Yang et al. Tumor‐Associated Monocytes Reprogram CD8+ T Cells into Central Memory‐Like Cells with Potent Antitumor Effects
CN112447264A (zh) 基于脱靶评估评价基因编辑治疗的方法
CN111939271A (zh) 一种血红蛋白病治疗有效性预测方法
Shannon The Molecular Biology of Sickle Cell Anaemia
CA3237748A1 (en) Biomarkers of megakaryocyte-derived extracellular vesicles
CN114222816A (zh) 一种高效修复环状铁粒幼细胞性贫血基因突变的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20220712

Address after: 510000 building 10, No.6 Nanjiang 2nd Road, Zhujiang street, Nansha District, Guangzhou City, Guangdong Province

Applicant after: Guangzhou Ji Yin Medical Technology Co.,Ltd.

Address before: 102206 2nd floor, building 2, No.22, kekeyuan Road, Changping District, Beijing

Applicant before: EDIGENE Inc.

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220401

WD01 Invention patent application deemed withdrawn after publication